FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988587516> ?p ?o ?g. }

• W2988587516 endingPage "10" @default.
• W2988587516 startingPage "3" @default.
• W2988587516 abstract "Immune-mediated inflammatory arthritis (IMIA) is a heterogeneous group of diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). Disease-modifying antirheumatic drugs (DMARDs) target very different cellular components of the disease processes. Characterization of the pathobiological subtypes of IMIA could provide more specific treatment approaches for each disease. For example, RA has been proposed to consist of at least three synovial pathotypes (lymphoid, myeloid, and fibroid), and only a subgroup of RA patients have erosive disease. The objective of this study was to evaluate the effects of various DMARDs on different synovial cell subsets using human ex vivo models of IMIA.Synovial fluid and blood samples were obtained from a study population consisting of patients with RA, PsA, or peripheral SpA with at least one swollen joint (n = 18). The DMARDs used in this study were methotrexate, adalimumab, etanercept, tocilizumab, anakinra, ustekinumab, secukinumab, tofacitinib, and baricitinib. Paired synovial fluid mononuclear cells (SFMCs), peripheral blood mononuclear cells (PBMCs), and fibroblast-like synovial cells (FLSs) were used in three different previously optimized ex vivo models.In SFMCs cultured for 48 hours, all DMARDs except anakinra decreased the production of monocyte chemoattractant protein (MCP)-1. In SFMCs cultured for 21 days, only the two tumor necrosis factor alpha (TNFα) inhibitors adalimumab and etanercept decreased the secretion of tartrate-resistant acid phosphatase (P < 0.01, P < 0.001). In the FLS and PBMC 48-hour co-cultures, only tocilizumab (P < 0.001) and the two Janus kinase inhibitors tofacitinib and baricitinib (both P < 0.05) decreased the production of MCP-1 by around 50%.TNFα inhibition was effective in preventing inflammatory osteoclastogenesis, whereas tocilizumab, tofacitinib, and baricitinib had superior efficacy in cultures dominated by FLSs. Taken together, this study reveals that responses to cytokine inhibitors associate with cellular composition in models of IMIA. In particular, this study provides new evidence on the differential effect of DMARDs on leukocytes compared with stromal cells." @default.
• W2988587516 created "2019-11-22" @default.
• W2988587516 creator A5009196904 @default.
• W2988587516 creator A5010914273 @default.
• W2988587516 creator A5022991298 @default.
• W2988587516 creator A5037090773 @default.
• W2988587516 creator A5057054913 @default.
• W2988587516 creator A5071248640 @default.
• W2988587516 date "2019-11-11" @default.
• W2988587516 modified "2023-10-15" @default.
• W2988587516 title "Responses to Cytokine Inhibitors Associated with Cellular Composition in Models of Immune‐Mediated Inflammatory Arthritis" @default.
• W2988587516 cites W1480981563 @default.
• W2988587516 cites W1851147669 @default.
• W2988587516 cites W1969354382 @default.
• W2988587516 cites W1969908269 @default.
• W2988587516 cites W1983541797 @default.
• W2988587516 cites W2005260135 @default.
• W2988587516 cites W2018148737 @default.
• W2988587516 cites W2046208657 @default.
• W2988587516 cites W2056813079 @default.
• W2988587516 cites W2064408454 @default.
• W2988587516 cites W2072270184 @default.
• W2988587516 cites W2077550414 @default.
• W2988587516 cites W2078052703 @default.
• W2988587516 cites W2102172358 @default.
• W2988587516 cites W2113633952 @default.
• W2988587516 cites W2114308202 @default.
• W2988587516 cites W2114768841 @default.
• W2988587516 cites W2118706017 @default.
• W2988587516 cites W2124162112 @default.
• W2988587516 cites W2124311688 @default.
• W2988587516 cites W2128787142 @default.
• W2988587516 cites W2133076005 @default.
• W2988587516 cites W2147060846 @default.
• W2988587516 cites W2154749149 @default.
• W2988587516 cites W2163632187 @default.
• W2988587516 cites W2165571611 @default.
• W2988587516 cites W2264875245 @default.
• W2988587516 cites W2294966323 @default.
• W2988587516 cites W2316508096 @default.
• W2988587516 cites W2319957449 @default.
• W2988587516 cites W2325183941 @default.
• W2988587516 cites W2415440360 @default.
• W2988587516 cites W2466516861 @default.
• W2988587516 cites W2518679748 @default.
• W2988587516 cites W2549234720 @default.
• W2988587516 cites W2611871093 @default.
• W2988587516 cites W2735347267 @default.
• W2988587516 cites W2746181579 @default.
• W2988587516 cites W2747487484 @default.
• W2988587516 cites W2762229810 @default.
• W2988587516 cites W2769516143 @default.
• W2988587516 cites W2789655418 @default.
• W2988587516 cites W2795500234 @default.
• W2988587516 cites W2889878720 @default.
• W2988587516 cites W2891552061 @default.
• W2988587516 cites W2909878427 @default.
• W2988587516 cites W2917800966 @default.
• W2988587516 doi "https://doi.org/10.1002/acr2.11094" @default.
• W2988587516 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6957916" @default.
• W2988587516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31943973" @default.
• W2988587516 hasPublicationYear "2019" @default.
• W2988587516 type Work @default.
• W2988587516 sameAs 2988587516 @default.
• W2988587516 citedByCount "18" @default.
• W2988587516 countsByYear W29885875162020 @default.
• W2988587516 countsByYear W29885875162021 @default.
• W2988587516 countsByYear W29885875162022 @default.
• W2988587516 countsByYear W29885875162023 @default.
• W2988587516 crossrefType "journal-article" @default.
• W2988587516 hasAuthorship W2988587516A5009196904 @default.
• W2988587516 hasAuthorship W2988587516A5010914273 @default.
• W2988587516 hasAuthorship W2988587516A5022991298 @default.
• W2988587516 hasAuthorship W2988587516A5037090773 @default.
• W2988587516 hasAuthorship W2988587516A5057054913 @default.
• W2988587516 hasAuthorship W2988587516A5071248640 @default.
• W2988587516 hasBestOaLocation W29885875161 @default.
• W2988587516 hasConcept C137061746 @default.
• W2988587516 hasConcept C142724271 @default.
• W2988587516 hasConcept C150903083 @default.
• W2988587516 hasConcept C17991360 @default.
• W2988587516 hasConcept C185592680 @default.
• W2988587516 hasConcept C202751555 @default.
• W2988587516 hasConcept C203014093 @default.
• W2988587516 hasConcept C204787440 @default.
• W2988587516 hasConcept C207001950 @default.
• W2988587516 hasConcept C26291073 @default.
• W2988587516 hasConcept C2776164576 @default.
• W2988587516 hasConcept C2776260265 @default.
• W2988587516 hasConcept C2776268809 @default.
• W2988587516 hasConcept C2777077863 @default.
• W2988587516 hasConcept C2777178219 @default.
• W2988587516 hasConcept C2777226972 @default.
• W2988587516 hasConcept C2777575956 @default.
• W2988587516 hasConcept C2778886723 @default.
• W2988587516 hasConcept C2779786854 @default.
• W2988587516 hasConcept C2780132546 @default.
• W2988587516 hasConcept C55493867 @default.

• next